Immunome, Inc. (NASDAQ:IMNM) Receives $23.20 Average Price Target from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $23.20.

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Saturday. Guggenheim reissued a “buy” rating and set a $25.00 price target on shares of Immunome in a research report on Monday, August 25th. The Goldman Sachs Group assumed coverage on Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 price target for the company. Craig Hallum assumed coverage on Immunome in a report on Friday, September 5th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Evercore ISI assumed coverage on Immunome in a report on Friday, August 22nd. They set an “outperform” rating and a $18.00 price objective on the stock.

Institutional Investors Weigh In On Immunome

Several hedge funds have recently made changes to their positions in IMNM. Teacher Retirement System of Texas boosted its holdings in Immunome by 6.8% in the second quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock valued at $172,000 after acquiring an additional 1,188 shares during the last quarter. Main Management ETF Advisors LLC boosted its holdings in Immunome by 1.6% in the second quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock valued at $716,000 after acquiring an additional 1,248 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Immunome by 3.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company’s stock valued at $470,000 after acquiring an additional 1,643 shares during the last quarter. Invesco Ltd. boosted its holdings in Immunome by 6.4% in the first quarter. Invesco Ltd. now owns 28,379 shares of the company’s stock valued at $191,000 after acquiring an additional 1,718 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Performance

Immunome stock opened at $15.69 on Wednesday. The stock has a fifty day moving average of $11.63 and a two-hundred day moving average of $9.89. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -5.09 and a beta of 1.94. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $17.32.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.02. The company had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. On average, analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.